Latest Earnings Results: Q2 '26
Estimated EPS
-$0.21
Reported EPS
-$0.14
Surprise
+33.33%
Estimated Rev
$21.45M
Reported Rev
$22.73M
Surprise
+5.95%
$HBIO Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.64 down -28.00% YoY • Reported revenue of $22.73M up 11.13% YoY • Harvard Bioscience expects full-year 2026 revenue growth between 3% and 5%, with adjusted gross margin between 57% and 59% and adjusted EBITDA growth between 6% and 10% for the year.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.17 | -- | -- | N/A |
Q2 '26 | -$0.21 | -$0.14 | 33.33% | BEAT |
Q1 '26 | -$0.62 | -$0.33 | 46.77% | BEAT |
Q4 '25 | $0.04 | $0.00 | -100.00% | MISSED |
Q3 '25 | $0.00 | $0.00 | -100.00% | MISSED |